Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synvista Therapeutics has reported results from a study demonstrating the role of haptoglobin typing in determining the risk of cardiovascular complications in patients with diabetes. The company has presented that tight glycemic control in patients with diabetes appears most effective in reducing cardiovascular events in patients who possess the haptoglobin2-2 phenotype.
Subscribe to our email newsletter
This large, prospective evaluation of haptoglobin (Hp) typing demonstrates how 40% of diabetic patients can achieve significant cardiovascular benefit from tight glycemic control.
The results of a prospective population-based study of more than 3,000 individuals age 55 or older with diabetes mellitus observed that Hp2-2 was associated with a highly significant increase in incidence of non-fatal-myocardial infarction, stroke and cardiovascular death, and that only patients with the Hp2-2 genotype (as compared to patients with genotypes Hp1-2 or Hp1-1) were shown to have a significant decrease in major cardiovascular events if their HbA1c was maintained below 7.0, the generally recommended target for tight glycemic control.
Noah Berkowitz, president and CEO of Synvista, said: “This study provides, for the first time, strong prospective evidence that tight glucose monitoring and control can dramatically benefit certain identifiable patients with diabetes. While it is widely accepted that tight glycemic control can limit microvascular disease like retinopathy in patients with diabetes, the potential benefits of such control on macrovascular disease have been less clear.”